JP Morgan Maintains Overweight on Enanta Pharmaceuticals, Lowers Price Target to $17
Benzinga Newsdesk 55 minutes ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
JP Morgan analyst Anupam Rama maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Overweight and lowers the price target from $19 to $17.
JP Morgan analyst Anupam Rama maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Overweight and lowers the price target from $19 to $17.
